C4 Therapeutics CFO acquires 6,250 shares

C4 Therapeutics’ CFO recorded RSU vesting, with a portion of shares withheld to cover taxes rather than sold on the market.

Rhea-AI Filing Summary

C4 Therapeutics, Inc. (CCCC) reported that Chief Financial Officer Kendra Adams had restricted stock units vest on September 18, 2026, resulting in the acquisition of 6,250 shares of Common Stock. Of these, 2,775 shares were withheld by the company to satisfy tax withholding obligations related to the RSU vesting and settlement, which is not characterized as a market sale.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Adams Kendra

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Common Stock F1	6,250	$0.00	$0.00
Tax Withholding	Common Stock F2	2,775	$3.39	$9K

Holdings After Transaction: Common Stock — 382,323 shares (Direct)

Footnotes (2)

1. F1. Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023.
2. F2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Key Figures

Shares acquired on RSU vesting: 6,250 shares Shares withheld for taxes: 2,775 shares Tax withholding valuation price: $3.39 per share

3 metrics

Shares acquired on RSU vesting 6,250 shares Common Stock acquired by CFO on September 18, 2026 upon RSU vesting

Shares withheld for taxes 2,775 shares Common Stock withheld by issuer to satisfy tax withholding obligations on RSU settlement

Tax withholding valuation price $3.39 per share Per-share value used for the 2,775 shares withheld for tax obligations

Key Terms

restricted stock units ("RSUs"), tax withholding obligations, withheld by the Issuer

3 terms

restricted stock units ("RSUs") financial

"Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligations financial

"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs."

withheld by the Issuer financial

"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transaction did CCCC report for its CFO on September 18, 2026?

The CFO, Kendra Adams, reported RSU vesting that resulted in the acquisition of 6,250 shares of C4 Therapeutics, Inc. Common Stock on September 18, 2026, from a previously disclosed restricted stock unit grant.

How many CCCC shares were acquired by the CFO through RSU vesting?

The CFO acquired 6,250 shares of C4 Therapeutics, Inc. Common Stock upon vesting of a previously reported RSU grant. This reflects settlement of restricted stock units into common shares.

How many CCCC shares were withheld to cover taxes for the CFO’s RSU vesting?

A total of 2,775 shares of C4 Therapeutics, Inc. Common Stock were withheld by the issuer to satisfy tax withholding obligations related to the RSU vesting and settlement for the CFO.

Did the CCCC CFO sell any shares in the reported Form 4 transaction?

The filing states that 2,775 shares were withheld by C4 Therapeutics, Inc. to satisfy tax withholding obligations and “does not represent a sale” by the CFO, so no market sale of shares is reported.

At what price per share were the withheld CCCC shares valued for tax purposes?

The 2,775 shares withheld to satisfy tax withholding obligations were valued at $3.39 per share according to the transaction data in the Form 4 filing.

Was the CCCC CFO’s Form 4 transaction under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not affirmed, and the footnotes do not state that these transactions were made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:26 PM Accepted by SEC EDGAR 09/21/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Kendra

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2026		M(1)	V	6,250	A	$0	385,098	D
Common Stock	09/18/2026		F(2)		2,775	D	$3.39	382,323	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023.

2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)